On September 11, 2023, Verona Pharma plc announced that the U.S. Food and Drug Administration has accepted for review the Company's New Drug Application for ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease. The FDA has assigned a Prescription Drug User Fee Act target action date of June 26, 2024 and is not currently planning to hold an advisory committee meeting to discuss the NDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.04 USD | +0.33% | -5.79% | -39.44% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.44% | 98Cr | |
+12.30% | 12TCr | |
+12.15% | 11TCr | |
-8.14% | 2.34TCr | |
-1.34% | 2.21TCr | |
-8.21% | 1.83TCr | |
-41.70% | 1.66TCr | |
-15.33% | 1.6TCr | |
+5.80% | 1.4TCr | |
+28.03% | 1.17TCr |
- Stock Market
- Equities
- VRNA Stock
- News Verona Pharma plc
- Verona Pharma plc Announces U.S. Food and Drug Administration Accepts for Review the Company's New Drug Application for Esifentrine for the Maintenance Treatment of Patients with Chronic Obstructive Pulmonary Disease